VDRM Record sales with good fundamentals. Great Technicals :)VDRM does appear to be under accumulation, some targets to the upside have been laid out. This is not financial advice.
VDRM trade ideas
VDRM FULL DD PACKAGEALL THE DD ON VDRM YOU NEED RIGHT HERE (repost)
2dollarbill Saturday, 08/19/17 10:19:12 AM
Re: None
Post #
26410
of 26411 Go
ALL THE DD ON VDRM YOU NEED RIGHT HERE
FDA approved products that ViaDerma (VDRM) offers:
-skin cancer therapies (Cantrile)
-stem cell therapy product (TetraStem Plus)
-topical antibiotics (TetraStem the world’s strongest broad-spectrum topical antibiotic available)
-TETRA-STEM – a tetracycline hydrochloride ointment. An award-winning antibiotic/wound healing product that kills all knows bacteria, including "flesh-eating" bacteria. Tertra-stem also can be used to treat wounds, ulcers
-topical anti-viral product (Viralcur) for genital herpes anti-fungal products for onychomycocis (OnyPro)
-hair loss prevention product (HairGain)
-ACNECLIR/ACNEEN – a salicylic acid based lotion that treats acne
-ECODERM – a colloidal oatmeal lotion for Eczema
-ACNECYCLINE – a tetracycline hydrochloride ointment that treats acne
-DERMONEEN – a salicylic acid lotion used to treat Psoriasis
-IVYMED – a zinc acetate based liquid that treats Poison Ivy rashes
- STAPHWASH PLUS – a zinc acetate based liquid. This is a non-antibiotic skin cleanser that kills MRSA
-TETRA-ABC – a tetracycline hydrochloride based ointment. This is an oil based topical antibiotic that kills all known bacterial infections. A water based version of this product is also available.
-STINGMED – a zinc acetate based liquid that treats most insect and spider bites
-ADVANCED JELLYFISH STING KIT – a zinc acetate powder, for suspension, that treats Jellyfish stings
-VENOMX – a zinc acetate based liquid used topically to treat snake bites.
-Product for treatment of Migraines presently; with a future of possibly ( inflammation of fibromyalgia, Cohn’s disease, nicotine addiction, schizophrenia, and pain management for Multiple Sclerosis and cancer. utilizing (CBD's) Calanoids and (THC) Tetrahydrocannabinol
biotechs trade at 30x earnings or 5x gross sales or 15x net sales or on air if they are a r and d company, with VDRM we have sales coming this year here is the analysis broken down below
ie...from the 500,000 bottles alone will yield $62.5M gross sales
$62.5m in gross sales X 5x gross sales = 325m market cap = $1.00 - $1.50 target
OR
62.5m in gross sales @ a 50% margin = $31m in net sales X 15x net sales = 450m market cap = $2.00 + target
OR
62.5m in gross sales with a $31m in net sales which divided by outstanding stock = 0.15 cents earnings X 30x earnings (pe - price to earnings) = $4.50 + target
Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transformoral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.
Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with
Finally!! FDA Number for Premature Ejaculation Drug IS IN! LOS ANGELES, CA--(Marketwired - June 27, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has received its National Drug Code (NDC) 69006-010-00 from the Food and Drug Administration (FDA) for its new over the counter or OTC medication, Prolayed, a male genital desensitizer to delay onset of ejaculation.
The company's FDA Registered Prolayed combines Lidocaine as the active ingredient with ViaDerma's proprietary transdermal delivery system. The new "OTC Drug" is now ready for sale. The Company's recent testing has proved to be successful. The market for Premature Ejaculation (PE) is estimated to be $1.3 billion in 2017. The Company's topical solution does not have to be ingested and processed through the body's internal organs. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues in the near future.
This is another product in the "Go to Market Strategies" pipeline. The Company already has located a suitable manufacturer and seeks distributors. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several new products.
Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company. Now, men can purchase the spray themselves directly from an online pharmacy. In other reported testing, the product works on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment market has been estimated to be approximately $1.3 Billion dollars for 2017, up from about $684 million dollars in 2010 based on the U.S. and European approval of several new products. Trends, Technologies & Opportunities Report for 2016-2020 with key vendors being Pfizer, Emcure, Eli Lilly. In Technavio's report, Global Premature Ejaculation Treatment Market for the 4-year period states that the analysts forecast for the global PE treatment market to grow at a CAGR of 9.65% during that period.
Company Update
The production of the Company's topical antibiotic is still on track and the Company is finalizing purchase orders for the product which should be shipped to distributors within the next few weeks. Also, the Company has had new inquiries from distributors in South Korea, and a meeting is scheduled in the first week of July to finalize a sales agreement. The lawsuit filed against the Company has been answered and the Company's legal counsel Austin Legal Group, from San Diego, has filed a motion to dismiss the plaintiffs' claims in Federal Court.
MM's shaking out weak handsNothing new here, seen this time and time again with VDRM.
Company gets good news and stock "tanks". Always rebounds and always comes back stronger.
Chart is still strong looking and once we get serious volume rolling in again I think we skyrocket straight to a nickel. FDA approval could push this even further to dime land.
We will see.
Longs must be patient, good things will come, do not fall for the tricks and get ruined by dirty tactics. Long and strong.
Millionaires will be made!
Great news today, I believe we see the start of a bull trendWith today's news, the fact that the case has the potential to be dismissed, and FDA approval on the horizon, I think today marks the start of a long bull trend for the rest of the summer.
VDRM continues to honor their word, and continues to show how much they care about investors. Happy to apart of this company and excited for the future.
Millionaires will be made!
ViaDerma, Inc. Commences First Manufacturing Run and will Meet tLOS ANGELES, CA--(Marketwired - June 12, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has commenced manufacturing of its FDA registered topical antibiotic. ViaDerma, Inc. has completed the quality control and approved labeling for the product and will begin distribution of the wound care drug in June. The "Quality Control" plan has been executed and now meets the strict guidelines starting with the manufacturer all the way through to the point of purchase. To assure a solid growth strategy, the Company's go to market expert and strategist, Ivan Klarich, has just returned from multi country Asian tour for ViaDerma where the product was well received. The Company is expecting several countries to order 10,000 units to begin the product launch in several Asian countries. The Company plans to continue to add additional products and offer those new products directly to the same distributors. The Company plans to announce additional new products for its proprietary specialty pharmaceutical product line in the very near future.
The Company's President, Dr. Christopher Otiko, said, "We are all pleased to have a product in manufacturing and to meet our goals. Our product manufacturer will be able to manufacture most of our products and we look forward to building a lasting relationship to deliver high quality pharmaceuticals to our distributors. Since my presentation at DFCON or the Diabetic Foot Global Conference in Houston, TX, in March, we have had a tremendous amount of interest in our topical antibiotic. Our goal is to have our product added to all diabetic foot ulcer treatment protocols around the globe."
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, a tetracycline-based topical antibiotic, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
FDA Approval "coming soon"From a post on ihub- an investor emailed investor relations and received this response $$$
to: info@viadermalicensing.com
cc: sales@viadermalicensing.com
subject: Update
mailed-by: gmail.com
Hello,
I have a few questions:
1-Can we expect a PR with a FDA approval this week or next for your product for treating Premature Ejaculation?
2-Are sales rolling out this quarter for Viabecline?
3-Will the lawsuit be dropped or settled this quarter? Will ViaDerma prevail?
4-Hasn't the efficacy already been done for Viabecline? Why have you started a new independent study in Texas to prove Viabecline's efficacy in treating diabetic foot wounds?
5-How much revenue do you expect from the grass roots THC and non-THC Cannabinoids, both in a patch form, roll on and spray signed with the Canadian company? Are your plans to sell licensing agreements to major producers?
Thank you
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
info@viadermalicensing.com
3:08 PM (17 hours ago)
FDA approval is on track. No delays are expected. Stand by for updates on that
Rollout is also still on time and should be out by the of the quarter (one month from now)
We received a continuance to submit our reply to the lawsuit. That's usually pretty standard. We will report developments as they happen but we feel very strongly we will prevail. We cant say too much until after we file our official reply with the court
Efficacy has been done but the reason for the independent study is to show we do it better.
Can't answer any revenue guidance question yet until we release that to the public. Hopefully soon. Stay tuned for more news in the near future. We expect to report on some of these and other developments shortly.
Thanks
Investor Relations
(310) 734 6111
Buying buying buyingCan't get enough VDRM at these prices!
Anyone who has been following my posts knows I'm very long on this stock and coming back down to these prices is a pure gift.
With the CEO speaking at a large conference at the end of the month, lots of eyes will be on this company.
$$'s by December or sooner IMO.
Millionaires will be made!
VDRM Brings in Ivan Klarich" ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has hired Mr. Ivan Klarich, who is an expert in managing the launching of "Go to Market" strategies for new product compliance. The Company wants to avoid the pitfalls often found in the launching a new product or product line. The Company wants to assure a solid strategy behind the launch for the labeling, marketing and distribution. The "Quality Control" plan will assure the product meets strict guidelines, starting with the manufacturer all the way through to the point of purchase. The Company plans to continue to hire several experts in the specialty pharmaceutical field as the Company rolls out an aggressive growth plan for 2017 and the years ahead."
Very excited for this PR and what it means for the long run for VDRM. Anyone who has been following my posts knows I'm very long long on this company in 2017.
I think we may see a 20% green day today, but even if we continue to go back down a bit I have no worries and will continuing buying more.
VDRM long and strong!
Millionaires will be made
Greatness Takes Time.I'm seeing some bashing of this company on a few other outlets.
I think one thing new investors into VDRM need to realize is that greatness takes time. If you bought into it at 0.06-0.07 because somebody told you it was going to run to a $1 overnight, that's all on the trader and not on the stock.
If you look at the chart, this is a very healthy company with a very healthy chart. Slow and steady is the way to go. This company is in store for greatness, and I do believe we see $1 in 2017/2018 however new traders need to realize that a jump from pennies to a dollar happens very rarely unless the company undergoes a R/S or has some suspicious activity going on with it.
If you are newly invested into VDRM and are currently sitting at a loss or near a loss I encourage you to hold tight and be patient. if you sell without the intent to buy back in, I suggest you ignore this ticker for the next year or so.
We will do great things, we have done great things, and great things will continue to happen slowly but surely with this stock.
Millionaires will be made.
VDRM long and strong!Posted about this one a few weeks and am still holding all my shares plus a few more.
This will be 2017's big winner IMO. Low floaters move FAST. The company has revolutionary patents pending as well as great news released last Friday about their new products.
It's extremely undervalued, and I know for a fact strong hands like myself will continue buying up the float.
As I said before, millionaires will be made with this one. Don't get left n the sidelines!
Strong hold/buy!Managed to pick up some more shares dirt cheap today during that dip.
I am very long on this stock and am extremely optimistic as to how it will before in 2017. This is a low floater, and the potential for gains is between 10k and 30k percent.
Long term hold, don't expect to get rich overnight with this one and be prepared to whether the storms but mark my words...millionaires will be made with this one.
$1.25 Price target (65k shares)2017 price target is $1.25, analysis shows me we should reach 1.25 or higher in the next 12 months. I had to sell $RNVA for +10% here as this play is too good to pass up. Company is EXTREMELY undervalued given the things in the work for 2017. Several patents, topical Viagra in the works, entrance into the Medical Marijuana sector...Company should also fair well and benefit from the repeal of Obamacare. This will be one to watch, lock in profits don't get emotional. Good money to be made long term.
